In period II, 4985 patients (56.6%) in the AD group had at least 1 major druggable sequence variation from more active molecular testing than period I (SMD = 0.67): EGFR variation (4376 patients), ALK rearrangement (457 patients), ROS1 rearrangement (40 patients), RET rearrangement (41 patients), BRAF V600E variation (22 patients), MET exon 14 skipping (14 patients), KRAS G12C variation (34 patients), and NTRK1/2/3 gene fusion (1 patient). This evidence concerns the gene ALK and Alzheimer disease.